Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

Simone Mocellin, Galen A. Ohnmacht, Ena Wang, Francesco M. Marincola

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Production of cytokines (CKs) in the tumor micro-environment may modulate tumor-host interactions. However, preclinical models often provide conflicting data and there is no established role for CKs as modulators of the natural or treatment-related behavior of tumors. Serial sampling by fine-needle aspirates (FNAs) of identical metastases from patients affected with metastatic melanoma and undergoing IL-2-based vaccination allowed prospective measurement of IL-10, TGF-β1, TGF-β2 and IFN-γ transcriptional levels assessed by quantitative real-time PCR. Thus, it was possible to prospectively document the expression of markers relevant to a given treatment and follow at the same time the clinical outcome of the lesions left in place. Eight of 27 metastatic lesions completely regressed in response to the treatment and I demonstrated >50% shrinkage. These regressions occurred after the follow-up FNA had been obtained. IL-10 transcript was differentially expressed in pre-treatment FNA of responding lesions (t-test p2 = 0.002). During treatment, INF-γ transcript levels significantly increased in regressing compared to non-regressing lesions (t-test p2 = 0.03). These data suggest that the pre-treatment CK profile of the tumor micro-environment may determine clinical responsiveness to immune therapy. Furthermore, temporal changes in CK expression during treatment might describe the biological characteristics of an effective immune response.

Original languageEnglish
Pages (from-to)236-242
Number of pages7
JournalInternational Journal of Cancer
Volume93
Issue number2
DOIs
Publication statusPublished - 15 Jul 2001
Externally publishedYes

Fingerprint

Melanoma
Cytokines
Neoplasm Metastasis
Needles
Therapeutics
Interleukin-10
Neoplasms
Interleukin-2
Real-Time Polymerase Chain Reaction
Vaccination

Keywords

  • Cytokine
  • Fine-needle aspiration
  • Immune response
  • Melanoma
  • Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. / Mocellin, Simone; Ohnmacht, Galen A.; Wang, Ena; Marincola, Francesco M.

In: International Journal of Cancer, Vol. 93, No. 2, 15.07.2001, p. 236-242.

Research output: Contribution to journalArticle

Mocellin, Simone ; Ohnmacht, Galen A. ; Wang, Ena ; Marincola, Francesco M. / Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. In: International Journal of Cancer. 2001 ; Vol. 93, No. 2. pp. 236-242.
@article{1bce90e853b44c30aa202a7bbb2488af,
title = "Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness",
abstract = "Production of cytokines (CKs) in the tumor micro-environment may modulate tumor-host interactions. However, preclinical models often provide conflicting data and there is no established role for CKs as modulators of the natural or treatment-related behavior of tumors. Serial sampling by fine-needle aspirates (FNAs) of identical metastases from patients affected with metastatic melanoma and undergoing IL-2-based vaccination allowed prospective measurement of IL-10, TGF-β1, TGF-β2 and IFN-γ transcriptional levels assessed by quantitative real-time PCR. Thus, it was possible to prospectively document the expression of markers relevant to a given treatment and follow at the same time the clinical outcome of the lesions left in place. Eight of 27 metastatic lesions completely regressed in response to the treatment and I demonstrated >50{\%} shrinkage. These regressions occurred after the follow-up FNA had been obtained. IL-10 transcript was differentially expressed in pre-treatment FNA of responding lesions (t-test p2 = 0.002). During treatment, INF-γ transcript levels significantly increased in regressing compared to non-regressing lesions (t-test p2 = 0.03). These data suggest that the pre-treatment CK profile of the tumor micro-environment may determine clinical responsiveness to immune therapy. Furthermore, temporal changes in CK expression during treatment might describe the biological characteristics of an effective immune response.",
keywords = "Cytokine, Fine-needle aspiration, Immune response, Melanoma, Metastasis",
author = "Simone Mocellin and Ohnmacht, {Galen A.} and Ena Wang and Marincola, {Francesco M.}",
year = "2001",
month = "7",
day = "15",
doi = "10.1002/ijc.1328",
language = "English",
volume = "93",
pages = "236--242",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

AU - Mocellin, Simone

AU - Ohnmacht, Galen A.

AU - Wang, Ena

AU - Marincola, Francesco M.

PY - 2001/7/15

Y1 - 2001/7/15

N2 - Production of cytokines (CKs) in the tumor micro-environment may modulate tumor-host interactions. However, preclinical models often provide conflicting data and there is no established role for CKs as modulators of the natural or treatment-related behavior of tumors. Serial sampling by fine-needle aspirates (FNAs) of identical metastases from patients affected with metastatic melanoma and undergoing IL-2-based vaccination allowed prospective measurement of IL-10, TGF-β1, TGF-β2 and IFN-γ transcriptional levels assessed by quantitative real-time PCR. Thus, it was possible to prospectively document the expression of markers relevant to a given treatment and follow at the same time the clinical outcome of the lesions left in place. Eight of 27 metastatic lesions completely regressed in response to the treatment and I demonstrated >50% shrinkage. These regressions occurred after the follow-up FNA had been obtained. IL-10 transcript was differentially expressed in pre-treatment FNA of responding lesions (t-test p2 = 0.002). During treatment, INF-γ transcript levels significantly increased in regressing compared to non-regressing lesions (t-test p2 = 0.03). These data suggest that the pre-treatment CK profile of the tumor micro-environment may determine clinical responsiveness to immune therapy. Furthermore, temporal changes in CK expression during treatment might describe the biological characteristics of an effective immune response.

AB - Production of cytokines (CKs) in the tumor micro-environment may modulate tumor-host interactions. However, preclinical models often provide conflicting data and there is no established role for CKs as modulators of the natural or treatment-related behavior of tumors. Serial sampling by fine-needle aspirates (FNAs) of identical metastases from patients affected with metastatic melanoma and undergoing IL-2-based vaccination allowed prospective measurement of IL-10, TGF-β1, TGF-β2 and IFN-γ transcriptional levels assessed by quantitative real-time PCR. Thus, it was possible to prospectively document the expression of markers relevant to a given treatment and follow at the same time the clinical outcome of the lesions left in place. Eight of 27 metastatic lesions completely regressed in response to the treatment and I demonstrated >50% shrinkage. These regressions occurred after the follow-up FNA had been obtained. IL-10 transcript was differentially expressed in pre-treatment FNA of responding lesions (t-test p2 = 0.002). During treatment, INF-γ transcript levels significantly increased in regressing compared to non-regressing lesions (t-test p2 = 0.03). These data suggest that the pre-treatment CK profile of the tumor micro-environment may determine clinical responsiveness to immune therapy. Furthermore, temporal changes in CK expression during treatment might describe the biological characteristics of an effective immune response.

KW - Cytokine

KW - Fine-needle aspiration

KW - Immune response

KW - Melanoma

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=0035879817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035879817&partnerID=8YFLogxK

U2 - 10.1002/ijc.1328

DO - 10.1002/ijc.1328

M3 - Article

VL - 93

SP - 236

EP - 242

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -